Literature DB >> 6439436

Oral glucose inhibits growth hormone secretion induced by human pancreatic growth hormone releasing factor 1-44 in normal man.

R R Davies, S Turner, D G Johnston.   

Abstract

The interaction between the inhibitory effect on growth hormone secretion of a 75 g oral glucose load and the stimulatory effect of human pancreatic growth hormone releasing factor 1-44 (hpGRF 1-44, 10 micrograms i.v.) has been studied in six normal subjects. hpGRF 1-44 alone induced a rise in growth hormone concentrations (maximum mean +/- SEM, 16.5 +/- 1.7 mU/l 15 min after injection) while growth hormone levels were suppressed by oral glucose alone (less than 1.5 mU/l from 45 to 135 min after glucose ingestion). When hpGRF 1-44 was injected 60 min after oral glucose, the growth hormone response was attenuated (maximum, 6.7 +/- 1.4 mU/l at 15 min, P less than 0.05). Increments of blood glucose within the physiological range diminish the growth hormone response to hpGRF 1-44 in normal man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439436     DOI: 10.1111/j.1365-2265.1984.tb03235.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 2.  Oral glucose tolerance test: an inhibitory or a stimulatory input to growth hormone secretion?

Authors:  R Valcavi
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

Review 3.  Regulation of growth hormone secretion in man: a review.

Authors:  D G Johnston; R R Davies; R W Prescott
Journal:  J R Soc Med       Date:  1985-04       Impact factor: 5.344

4.  The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.

Authors:  P Limone; S E Oleandri; P Ajmone Catt; S Grottoli; C Frangioni; E Avogadri; M Perrin; M R Valetto; M Maccario
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

5.  Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.

Authors:  S Grottoli; P Razzore; E Arvat; S E Oleandri; R Rossetto; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

6.  Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome.

Authors:  Keiyu Oshida; David J Waxman; J Christopher Corton
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.